pituitary gigantism


Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to pituitary gigantism: acromegaly, acromegalic gigantism

gigantism

 [ji-gan´tizm, ji´gan-tizm]
abnormal overgrowth of the body or a part; excessive size and stature. Generally applied to a rare abnormality of the pituitary gland, which secretes excessive growth hormone before the growing ends of the bones have closed. This causes a child to become an unusually tall adult; if the abnormality is extreme, the individual may reach a height of 2.4 meters (8 feet) or more, although the body proportions usually are normal.

The opposite condition, dwarfism, is caused by underproduction of the same hormone. (Overproduction of growth hormone in adults causes acromegaly.) Gigantism can be corrected only by early diagnosis in childhood and removal by surgery of part of the pituitary gland or by x-ray treatment.
cerebral gigantism gigantism in the absence of increased levels of growth hormone, attributed to a cerebral defect; infants are large, and accelerated growth continues for the first 4 or 5 years, the rate being normal thereafter. The hands and feet are large, the head is large, narrow and long, and the eyes have an antimongoloid slant with an abnormally wide space between them. The child is clumsy, and mental retardation of varying degree is usually present. Called also Sotos syndrome.
pituitary gigantism that caused by oversecretion of growth hormone by the pituitary gland; see gigantism. Called also Launois syndrome.

pi·tu·i·tar·y gi·gan·tism

a form of gigantism caused by hypersecretion of pituitary growth hormone; a rare disorder commonly the result of a pituitary adenoma.

pi·tu·i·tar·y gi·gan·tism

(pi-tū'i-tar-ē jī-gant'izm)
A form of gigantism caused by hypersecretion of pituitary growth hormone; a rare disorder commonly the result of a pituitary adenoma.
References in periodicals archive ?
Novartis, Basel, Switzerland, has announced that the Japanese health authority has approved Sandostatin LAR (octreotide acetate for injectable suspension) for the treatment of acromegaly and pituitary gigantism which is unresponsive to or unsuitable for surgery or other drug therapies, and for symptoms associated with gastrointestinal hormone secreting tumors (also known as gastroenteropancreatic (GEP) neuroendocrine tumors (NET), including carcinoid tumors, gastrinomas, and VIPomas (Vasoactive Intestinal Peptide- secreting tumors).
Teijin Pharma Limited, the core company of the Teijin Group's healthcare business, and Ipsen (Euronext: IPN; ADR: IPSEY) (Paris:IPN), today announced the launch of Somatuline([R]) 60/90/120 mg for subcutaneous injection in Japan for the treatment of acromegaly and pituitary gigantism (when response to surgical therapies is not satisfactory or surgical therapies are difficult to perform).
Teijin Pharma Limited, the core company of the Teijin Group's healthcare business, and Ipsen, today announced the launch of Somatuline 60/90/120 mg for subcutaneous injection in Japan for the treatment of acromegaly and pituitary gigantism (when response to surgical therapies is not satisfactory or surgical therapies are difficult to perform).